1. Home
  2. FUNC vs MGNX Comparison

FUNC vs MGNX Comparison

Compare FUNC & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FUNC

First United Corporation

HOLD

Current Price

$44.30

Market Cap

283.6M

Sector

Finance

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.33

Market Cap

280.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUNC
MGNX
Founded
1900
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
283.6M
280.3M
IPO Year
2012
2013

Fundamental Metrics

Financial Performance
Metric
FUNC
MGNX
Price
$44.30
$4.33
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
9.6K
469.4K
Earning Date
04-20-2026
05-08-2026
Dividend Yield
2.80%
N/A
EPS Growth
19.68
N/A
EPS
1.90
N/A
Revenue
$18,426,000.00
$149,500,000.00
Revenue This Year
$13.05
N/A
Revenue Next Year
$6.56
$3.19
P/E Ratio
$23.34
N/A
Revenue Growth
4.01
N/A
52 Week Low
$33.54
$1.30
52 Week High
$46.30
$5.08

Technical Indicators

Market Signals
Indicator
FUNC
MGNX
Relative Strength Index (RSI) 51.58 56.31
Support Level $43.48 $3.80
Resistance Level $46.14 $4.38
Average True Range (ATR) 1.13 0.19
MACD 0.08 0.04
Stochastic Oscillator 72.16 74.17

Price Performance

Historical Comparison
FUNC
MGNX

About FUNC First United Corporation

First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: